688098 申联生物
已收盘 10-12 15:00:00
资讯
新帖
简况
【机构调研记录】博时基金调研申联生物
证券之星 · 09-22
【机构调研记录】博时基金调研申联生物
【机构调研记录】华安基金调研悦安新材、申联生物
证券之星 · 09-22
【机构调研记录】华安基金调研悦安新材、申联生物
申联生物：9月20日召开分析师会议，兴业证券、国海证券等多家机构参与
证券之星 · 09-21
申联生物：9月20日召开分析师会议，兴业证券、国海证券等多家机构参与
申联生物（688098）披露UB-221治疗慢性自发性荨麻疹II期临床试验达到主要终点，9月21日股价上涨4.08%
证券之星 · 09-21
申联生物（688098）披露UB-221治疗慢性自发性荨麻疹II期临床试验达到主要终点，9月21日股价上涨4.08%
申联生物：UB-221治疗慢性自发性荨麻疹II期临床试验达主要终点
美股速递 · 09-20
申联生物：UB-221治疗慢性自发性荨麻疹II期临床试验达主要终点
申联生物最新公告：UB-221治疗慢性自发性荨麻疹II期临床试验达主要终点
证券之星 · 09-20
申联生物最新公告：UB-221治疗慢性自发性荨麻疹II期临床试验达主要终点
股市必读：申联生物（688098）9月16日董秘有最新回复
证券之星 · 09-17
股市必读：申联生物（688098）9月16日董秘有最新回复
股市必读：申联生物（688098）9月7日董秘有最新回复
证券之星 · 09-08
股市必读：申联生物（688098）9月7日董秘有最新回复
每周股票复盘：申联生物（688098）上半年营收下滑至1.12亿元
证券之星 · 09-06
每周股票复盘：申联生物（688098）上半年营收下滑至1.12亿元
图解申联生物中报：第二季度单季净利润同比下降76.81%
证券之星 · 08-30
图解申联生物中报：第二季度单季净利润同比下降76.81%
申联生物(688098)6月30日股东户数0.93万户，较上期减少7.66%
证券之星 · 08-30
申联生物(688098)6月30日股东户数0.93万户，较上期减少7.66%
申联生物(688098.SH)发布半年度业绩，归母净亏损1914.64万元
智通财经 · 08-30
申联生物(688098.SH)发布半年度业绩，归母净亏损1914.64万元
股市必读：申联生物（688098）8月25日董秘有最新回复
证券之星 · 08-26
股市必读：申联生物（688098）8月25日董秘有最新回复
申联生物最新公告：获批猪口蹄疫O型、南非1型二价合成肽疫苗兽药产品批准文号
证券之星 · 08-25
申联生物最新公告：获批猪口蹄疫O型、南非1型二价合成肽疫苗兽药产品批准文号
申联生物：公司不存在应披露而未披露的重大事项
证券之星 · 08-17
申联生物：公司不存在应披露而未披露的重大事项
股市必读：申联生物（688098）8月7日董秘有最新回复
证券之星 · 08-10
股市必读：申联生物（688098）8月7日董秘有最新回复
申联生物：公司将持续以实际行动夯实内在价值
证券日报网 · 08-07
申联生物：公司将持续以实际行动夯实内在价值
申联生物：持续深耕动保业务，加速推进南非1型口蹄疫疫苗等新产品的销售节奏
证券之星 · 08-07
申联生物：持续深耕动保业务，加速推进南非1型口蹄疫疫苗等新产品的销售节奏
申联生物：员工规模变化系公司基于业务需求动态调整
证券之星 · 08-07
申联生物：员工规模变化系公司基于业务需求动态调整
申联生物：当前公司经营稳健，各项业务有序推进
证券之星 · 08-03
申联生物：当前公司经营稳健，各项业务有序推进
加载更多
公司概况
公司名称：
申联生物医药(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2019-10-28
主营业务：
申联生物医药(上海)股份有限公司的主营业务是创新生物制品的研发、生产与商业化。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、猪瘟E2亚单位疫苗、人用创新药。
发行价格：
8.80
{"stockData":{"symbol":"688098","market":"SH","secType":"STK","nameCN":"申联生物","latestPrice":8.21,"timestamp":1791788400000,"preClose":8.32,"halted":0,"volume":2568941,"delay":0,"changeRate":-0.0132,"floatShares":411000000,"shares":411000000,"eps":-0.0652,"marketStatus":"已收盘","change":-0.11,"latestTime":"10-12 15:00:00","open":8.32,"high":8.4,"low":8.14,"amount":21200100,"amplitude":0.0312,"askPrice":8.21,"askSize":45,"bidPrice":8.2,"bidSize":283,"shortable":0,"etf":0,"ttmEps":-0.0652,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":5,"adr":0,"adjPreClose":8.32,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791768600000,1791775800000],[1791781200000,1791788400000]],"highLimit":9.15,"lowLimit":7.49,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":410644000,"isCdr":false,"pbRate":2.43,"roa":"--","roe":"--","epsLYR":-0.05,"committee":0.124842,"marketValue":3371000000,"turnoverRate":0.0063,"status":1,"afterMarket":{"amount":0,"volume":0,"close":8.21,"buyVolume":0,"sellVolume":0,"time":1791790437746,"indexStatus":"已收盘 10-12 15:30:00","preClose":8.32},"floatMarketCap":3371000000},"requestUrl":"/m/hq/s/688098","defaultTab":"news","newsList":[{"id":"2669994941","title":"【机构调研记录】博时基金调研申联生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2669994941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669994941?lang=zh_cn&edition=full","pubTime":"2026-09-22 08:07","pubTimestamp":1790035669,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月21日披露的机构调研信息，博时基金近期对1家上市公司进行了调研，相关名单如下：1）申联生物 调研纪要：公司计划基于II期优异数据快速推进UB-221用于CSU的III期临床，暂不探索更长给药间隔，以加速上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200004378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669719941","title":"【机构调研记录】华安基金调研悦安新材、申联生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2669719941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669719941?lang=zh_cn&edition=full","pubTime":"2026-09-22 08:07","pubTimestamp":1790035665,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月21日披露的机构调研信息，华安基金近期对2家上市公司进行了调研，相关名单如下：1）悦安新材 调研纪要：宁夏悦安3,000吨羰基铁粉示范线处于调试爬坡阶段，年内已贡献部分产量，后续将逐步扩大生产规模。羰基铁粉应用于汽车智能悬挂系统，已进入整车供应链。旗下最近一年表现最佳的公募基金产品为华安半导体产业股票发起式A，最新单位净值为2.46，近一年增长77.54%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200004373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0256","688786","BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316179","title":"申联生物：9月20日召开分析师会议，兴业证券、国海证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669316179?lang=zh_cn&edition=full","pubTime":"2026-09-21 23:03","pubTimestamp":1790003008,"startTime":"0","endTime":"0","summary":"在生产方面，UB-221的III期临床用药生产已放大至约2000L规模，届时需向监管机构更新CMC相关信息。关于“患者组别”等更细化的分层设计，目前暂未完全确定，将以届时与CDE确认的方案为准。这类分子在药物浓度不足以有效中和IgE后，疗效可能随暴露水平下降而落。在美国开发方面，合作方CUE已披露其向FD提交食物过敏适应症的II期临床申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100032767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0276","BK0012","BK0239","688098","601377","000750","BK0183","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154159","title":"申联生物（688098）披露UB-221治疗慢性自发性荨麻疹II期临床试验达到主要终点，9月21日股价上涨4.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669154159?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:36","pubTimestamp":1789983387,"startTime":"0","endTime":"0","summary":"截至2026年9月21日收盘，申联生物报收于8.68元，较前一交易日上涨4.08%，最新总市值为35.64亿元。近日，申联生物披露《关于UB-221治疗慢性自发性荨麻疹的II期临床试验达到主要终点的自愿性披露公告》。公告显示，公司控股孙公司扬州世之源自主研发的UB-221注射液治疗慢性自发性荨麻疹的II期临床试验达到主要终点，结果显示在第12周风团完全消退率呈剂量-反应关系，4mg/kg、2mg/kg、1mg/kg组应答率分别为54%、53%、43%，显著高于安慰剂组11%，优于奥马珠单抗组41%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100022430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126785009","title":"申联生物：UB-221治疗慢性自发性荨麻疹II期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1126785009","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126785009?lang=zh_cn&edition=full","pubTime":"2026-09-20 15:52","pubTimestamp":1789890732,"startTime":"0","endTime":"0","summary":"申联生物宣布，其研发的UB-221在针对慢性自发性荨麻疹的II期临床试验中，成功达成主要研究终点。这一进展标志着该候选药物在治疗路径上迈出关键一步。慢性自发性荨麻疹是一种顽固性疾病，患者常遭受反复发作的瘙痒与风团困扰，严重影响生活质量。UB-221的这项临床结果，或为这一长期缺乏有效疗法的领域带来新希望。申联生物方面表示，此次试验数据的积极表现，不仅验证了药物的初步疗效，也为后续更大规模的临床研究奠定了坚实基础。市场分析人士指出，该消息对申联生物在创新药领域的布局具有积极意义，公司未来研发管线价值有望进一步提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668183907","title":"申联生物最新公告：UB-221治疗慢性自发性荨麻疹II期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2668183907","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668183907?lang=zh_cn&edition=full","pubTime":"2026-09-20 15:41","pubTimestamp":1789890083,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司控股孙公司世之源自主研发的1类生物药UB-221注射液治疗慢性自发性荨麻疹的II期临床研究达到主要终点，并取得积极顶线结果。该研究共纳入145例受试者，UB-221各剂量组第12周HSS7=0应答率分别为54%、53%及43%，均显著高于安慰剂组的11%。安全性方面，UB-221总体耐受性良好，未发生与治疗相关的严重不良事件。上述事项预计短期内对公司业绩无重大影响，后续尚需完成III期临床研究及新药上市申请等程序。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000002759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668987107","title":"股市必读：申联生物（688098）9月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2668987107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668987107?lang=zh_cn&edition=full","pubTime":"2026-09-17 01:03","pubTimestamp":1789578196,"startTime":"0","endTime":"0","summary":"截至2026年9月16日收盘，申联生物报收于7.94元，下跌0.5%，换手率0.41%，成交量1.69万手，成交额1340.03万元。董秘最新回复投资者： 董秘你好！目前股价来看，连续20天交易低于800万元要被强制退市的，现在每天交易额就是玩擦边不退市。当日关注点交易信息汇总：9月16日主力资金净流入49.3万元，占总成交额3.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700000584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665310359","title":"股市必读：申联生物（688098）9月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2665310359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665310359?lang=zh_cn&edition=full","pubTime":"2026-09-08 01:00","pubTimestamp":1788800444,"startTime":"0","endTime":"0","summary":"截至2026年9月7日收盘，申联生物报收于8.3元，下跌0.6%，换手率0.68%，成交量2.78万手，成交额2327.15万元。本次担保对应的是并购贷款，贷款资金专项用于支付收购世之源的交易价款，并最终由本天成分步投入控股孙公司世之源，专项支持其创新药管线的临床试验推进。本次担保事项已严格按照法律法规及公司相关制度规定履行审议及信息披露义务，决策过程合法合规，不存在损害公司及中小股东利益的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366801","title":"每周股票复盘：申联生物（688098）上半年营收下滑至1.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366801","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366801?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:08","pubTimestamp":1788635293,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，申联生物报收于8.35元，较上周的8.26元上涨1.09%。本周，申联生物9月4日盘中最高价报8.56元。本周关注点来自业绩披露要点：申联生物2026年上半年营业收入111,920,730.05元，同比下降8.05%。截至公告日，公司及控股子公司对外担保总额不超过20,800万元，占公司2025年经审计净资产的14.97%，无逾期担保。申联生物医药（上海）股份有限公司于2026年8月28日发布《2026年度“提质增效重回报”行动方案的半年度评估报告》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663041810","title":"图解申联生物中报：第二季度单季净利润同比下降76.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663041810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663041810?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:48","pubTimestamp":1788083302,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物2026年中报显示，上半年度公司主营收入1.12亿元，同比下降8.05%；归母净利润-1914.64万元，同比下降48.77%；扣非净利润-1915.58万元，同比下降14.05%；其中2026年第二季度，公司单季度主营收入4932.23万元，同比上升14.75%；单季度归母净利润-1741.54万元，同比下降76.81%；单季度扣非净利润-1732.59万元，同比下降40.34%；负债率9.85%，投资收益-105.22万元，财务费用5.17万元，毛利率57.36%。财报数据概要请见下图:本文数据来源于申联生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000012960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049177","title":"申联生物(688098)6月30日股东户数0.93万户，较上期减少7.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049177","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663049177?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080859,"startTime":"0","endTime":"0","summary":"证券之星消息，近日申联生物披露，截至2026年6月30日公司股东户数为9297.0户，较3月31日减少771.0户，减幅为7.66%。在动物保健行业个股中，申联生物股东户数低于行业平均水平，截至6月30日，动物保健行业平均股东户数为1.86万户。从股价来看，2026年3月31日至2026年6月30日，申联生物区间跌幅为0.46%，在此期间股东户数减少771.0户，减幅为7.66%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049983","title":"申联生物(688098.SH)发布半年度业绩，归母净亏损1914.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049983","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663049983?lang=zh_cn&edition=full","pubTime":"2026-08-30 16:49","pubTimestamp":1788079743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，申联生物 发布2026年半年度报告，报告期内，公司实现营业收入1.12亿元，同比下降8.05%;归属于上市公司股东的净亏损1914.64万元;归属于上市公司股东的扣除非经常性损益的净亏损1915.58万元;基本每股收益-0.05元。若剔除上半年生物制品增值税税率变动影响，按上年同期口径模拟测算，报告期内营业收入及净利润同比均略有增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662765398","title":"股市必读：申联生物（688098）8月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2662765398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662765398?lang=zh_cn&edition=full","pubTime":"2026-08-26 08:42","pubTimestamp":1787704970,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，申联生物报收于8.12元，上涨1.5%，换手率0.53%，成交量2.2万手，成交额1769.12万元。董秘最新回复投资者： 董秘你好！公司年报说在研管线UB-421今年上半年申报CDE临床试验，现在已经8月底了还没申报，也没有对外公告，是不是触发虚假宣传信披违规？请董秘抽空回答一下！当日关注点交易信息汇总：8月25日主力资金净流入118.39万元，占总成交额6.69%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600014953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662573198","title":"申联生物最新公告：获批猪口蹄疫O型、南非1型二价合成肽疫苗兽药产品批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2662573198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662573198?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:41","pubTimestamp":1787658062,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司兰州分公司获批生产猪口蹄疫O型、南非1型二价合成肽疫苗(多肽MYA98-22+CATH-24+SAT1-26)，并取得兽药产品临时批准文号批件。该产品为合成多肽技术路线疫苗，与公司此前获批的两款含南非1型灭活疫苗形成互补，构建起覆盖猪、牛、羊的南非1型口蹄疫疫苗产品矩阵。产品上市销售前尚需履行批签发等程序，具体销售受防疫政策、市场容量等因素影响，收益存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500042881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660488745","title":"申联生物：公司不存在应披露而未披露的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2660488745","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660488745?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:03","pubTimestamp":1786953789,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物08月17日在投资者关系平台上答复投资者关心的问题。最近三个月创新药在二级市场的股价几乎都已经翻倍，而标榜着创新药的申联生物不但没有上涨还是下跌的！公司始终严格遵守信息披露规则，不存在应披露而未披露的重大事项。二级市场股价受多重因素影响，短期的波动不代表公司长期价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700018191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608411","title":"股市必读：申联生物（688098）8月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608411?lang=zh_cn&edition=full","pubTime":"2026-08-10 03:18","pubTimestamp":1786303094,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，申联生物报收于8.61元，上涨2.38%，换手率1.16%，成交量4.74万手，成交额3989.48万元。董秘最新回复投资者： 生物医药赛道行业竞争日趋激烈，对比同行表现，去年公司员工数量下降4.09%，人均营收小幅下滑。当日关注点交易信息汇总：8月7日主力资金净流入1.15万元，占总成交额0.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657291644","title":"申联生物：公司将持续以实际行动夯实内在价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2657291644","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657291644?lang=zh_cn&edition=full","pubTime":"2026-08-07 22:02","pubTimestamp":1786111320,"startTime":"0","endTime":"0","summary":"证券日报网讯8月7日，申联生物在互动平台回答投资者提问时表示，公司股价受多重因素影响，公司始终高度重视市值表现。一方面，公司持续深耕动保业务，加速推进南非1型口蹄疫疫苗等新产品的销售节奏，提升动保业务的销售规模和盈利水平；同时深化“动保+人药”双轮驱动战略，加快创新药管线研发。另一方面，公司强化精细化管理，严控成本费用，持续改善盈利基本面。此外，公司通过多渠道与投资者保持沟通，全面传递长期成长逻辑。公司将持续以实际行动夯实内在价值，全力提振市场信心。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyf3045904.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyf3045904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657134016","title":"申联生物：持续深耕动保业务，加速推进南非1型口蹄疫疫苗等新产品的销售节奏","url":"https://stock-news.laohu8.com/highlight/detail?id=2657134016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657134016?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:03","pubTimestamp":1786089795,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物08月07日在投资者关系平台上答复投资者关心的问题。公司股价受多重因素影响，我们始终高度重视市值表现。一方面，公司持续深耕动保业务，加速推进南非1型口蹄疫疫苗等新产品的销售节奏，提升动保业务的销售规模和盈利水平；同时深化“动保+人药”双轮驱动战略，加快创新药管线研发。公司将持续以实际行动夯实内在价值，全力提振市场信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700024659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688098"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657361349","title":"申联生物：员工规模变化系公司基于业务需求动态调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2657361349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657361349?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:03","pubTimestamp":1786089793,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物08月07日在投资者关系平台上答复投资者关心的问题。员工规模变化系公司基于业务需求动态调整，叠加提质增效、组织优化的内部安排共同所致，主要对低效岗位开展结构性梳理，同步布局新增及重点业务人才，核心骨干团队保持稳定。后续公司无大规模人员优化计划，人员将结合业务、管线进展动态调配，优先保障产品临床、研发、销售等核心岗位人才供给。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700024653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656321371","title":"申联生物：当前公司经营稳健，各项业务有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2656321371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656321371?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:06","pubTimestamp":1785744377,"startTime":"0","endTime":"0","summary":"证券之星消息，申联生物(688098)08月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问申联生物，贵司是否有何重大利空消息隐匿未报？造成二级市场股价一蹶不振？申联生物回复：尊敬的投资者，您好！二级市场股价波动受宏观经济环境、市场资金等多重因素影响。当前公司经营稳健，各项业务有序推进，严格按照上交所信息披露要求规范开展信息披露工作，不存在应披露未披露的重大事项。感谢您对公司的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300018570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791844548167,"stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":0.0173},{"period":"3month","weight":-0.0857},{"period":"6month","weight":-0.0938},{"period":"1year","weight":-0.2075},{"period":"ytd","weight":-0.0755}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"申联生物医药(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9297人(较上一季度减少7.66%)","perCapita":"44169股","listingDate":"2019-10-28","address":"上海市闵行区江川东路48号","registeredCapital":"41064万元","survey":" 申联生物医药(上海)股份有限公司的主营业务是创新生物制品的研发、生产与商业化。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、猪瘟E2亚单位疫苗、人用创新药。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"申联生物,688098,申联生物股票,申联生物股票老虎,申联生物股票老虎国际,申联生物行情,申联生物股票行情,申联生物股价,申联生物股市,申联生物股票价格,申联生物股票交易,申联生物股票购买,申联生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}